HER2 testing and its predictive utility in anti-HER2 breast cancer therapy

Pooja P. Advani; Jennifer A. Crozier; Edith A. Perez

doi:10.2217/bmm.14.95

HER2 testing and its predictive utility in anti-HER2 breast cancer therapy

Pooja P. Advani, Jennifer A. Crozier, Edith A. Perez

Hematology / Oncology / Cancer Center / Breast Clinic

Research output: Contribution to journal › Review article › peer-review

4 Scopus citations

Abstract

Breast cancer treatment is dependent on accurate pathologic diagnosis. HER2 testing is now universally recommended as part of evaluation of invasive breast cancer. HER2 testing is available via various slide and non-slide based assays, and interpretation of results continues to evolve. Herein we review these testing modalities and their incorporation into the 2013 ASCO/CAP guidelines. Once accurate HER2 status has been established the proper treatment based on recent clinical trials can be instituted.

Original language	English (US)
Pages (from-to)	35-49
Number of pages	15
Journal	Biomarkers in Medicine
Volume	9
Issue number	1
DOIs	https://doi.org/10.2217/bmm.14.95
State	Published - Jan 1 2015

Keywords

American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines
HER2 testing
breast cancer
immunohistochemistry (IHC)
in situ hybridization (ISH)
trastuzumab

ASJC Scopus subject areas

Drug Discovery
Clinical Biochemistry
Biochemistry, medical

Access to Document

10.2217/bmm.14.95

Cite this

@article{bb1565e99815409fbb9d767fa33efbc0,

title = "HER2 testing and its predictive utility in anti-HER2 breast cancer therapy",

abstract = "Breast cancer treatment is dependent on accurate pathologic diagnosis. HER2 testing is now universally recommended as part of evaluation of invasive breast cancer. HER2 testing is available via various slide and non-slide based assays, and interpretation of results continues to evolve. Herein we review these testing modalities and their incorporation into the 2013 ASCO/CAP guidelines. Once accurate HER2 status has been established the proper treatment based on recent clinical trials can be instituted.",

keywords = "American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines, HER2 testing, breast cancer, immunohistochemistry (IHC), in situ hybridization (ISH), trastuzumab",

author = "Advani, {Pooja P.} and Crozier, {Jennifer A.} and Perez, {Edith A.}",

note = "Publisher Copyright: {\textcopyright} 2015 Future Medicine Ltd.",

year = "2015",

month = jan,

day = "1",

doi = "10.2217/bmm.14.95",

language = "English (US)",

volume = "9",

pages = "35--49",

journal = "Biomarkers in Medicine",

issn = "1752-0363",

publisher = "Future Medicine Ltd.",

number = "1",

}

TY - JOUR

T1 - HER2 testing and its predictive utility in anti-HER2 breast cancer therapy

AU - Advani, Pooja P.

AU - Crozier, Jennifer A.

AU - Perez, Edith A.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Breast cancer treatment is dependent on accurate pathologic diagnosis. HER2 testing is now universally recommended as part of evaluation of invasive breast cancer. HER2 testing is available via various slide and non-slide based assays, and interpretation of results continues to evolve. Herein we review these testing modalities and their incorporation into the 2013 ASCO/CAP guidelines. Once accurate HER2 status has been established the proper treatment based on recent clinical trials can be instituted.

AB - Breast cancer treatment is dependent on accurate pathologic diagnosis. HER2 testing is now universally recommended as part of evaluation of invasive breast cancer. HER2 testing is available via various slide and non-slide based assays, and interpretation of results continues to evolve. Herein we review these testing modalities and their incorporation into the 2013 ASCO/CAP guidelines. Once accurate HER2 status has been established the proper treatment based on recent clinical trials can be instituted.

KW - American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines

KW - HER2 testing

KW - breast cancer

KW - immunohistochemistry (IHC)

KW - in situ hybridization (ISH)

KW - trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=84921689172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921689172&partnerID=8YFLogxK

U2 - 10.2217/bmm.14.95

DO - 10.2217/bmm.14.95

M3 - Review article

C2 - 25605454

AN - SCOPUS:84921689172

SN - 1752-0363

VL - 9

SP - 35

EP - 49

JO - Biomarkers in Medicine

JF - Biomarkers in Medicine

IS - 1

ER -

HER2 testing and its predictive utility in anti-HER2 breast cancer therapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this